Asia Pacific Psychedelic Drugs Market
시장 규모 (USD 10억)
연평균 성장률 : %
예측 기간 |
2022 –2029 |
시장 규모(기준 연도) |
USD 27.24 Million |
시장 규모(예측 연도) |
USD 63.70 Million |
연평균 성장률 |
|
주요 시장 플레이어 |
>아시아 태평양 환각제 시장, 출처(합성 및 천연), 유형(감정병원성 물질 , 해리성 물질 및 기타), 약물 (감마-하이드록시뷰티르산, 케타민, 실로시빈, 기타), 응용 분야(발작성 졸음증, 치료 저항성 우울증, 주요 우울 장애, 아편 중독, 외상 후 스트레스 장애, 기타), 투여 경로(경구, 흡입, 주사), 최종 사용자(병원, 전문 클리닉, 홈 케어, 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국) 산업 동향 및 2029년까지의 예측.
아시아 태평양 환각제 시장 분석 및 통찰력
환각제에는 리저산 디에틸아미드(LSD)와 식물에서 추출한 화학 물질을 포함한 다양한 유형의 화학 물질이 포함됩니다. 이러한 약물은 감각적 지각, 사고 과정, 에너지 수준을 변경하거나 향상시키는 능력이 있으며 영적 경험을 촉진하는 것으로도 보고되었습니다.
환각제는 공감제와 해리성 약물(예: 페닐사이클로헥실 피페리딘(PCP))과 세로토닌성(고전적 환각제)인 LSD로 분류할 수 있습니다. 두 유형의 환각제 모두 환각과 감각을 유발할 수 있으며, 더욱이 해리성 약물은 사람을 신체나 환경에서 통제 불능 상태로 만들고 단절감을 느끼게 할 수 있습니다. 출처에 따라 환각제는 천연 및 합성 유형으로 분류되었습니다.
이 약물은 주요 우울 장애, 외상 후 스트레스 장애, 공황 장애 , 치료 저항성 우울증 및 아편 중독 등의 치료에 광범위하게 사용됩니다. 환각제는 또한 lysergic acid 유도체(LSD)와 같은 여러 다른 이름으로 알려져 있으며, 이는 blotter, dots, sugar, acid, trips 및 window pane이라고도 알려져 있고, ketamine은 비타민 K, bump, green, K/special K, purple 및 super acid라고도 알려져 있으며, PCP는 angel/angel dust, boat/love boat, peace, killer weed, super grass 및 ozone이라고도 알려져 있습니다.
아시아 태평양 환각제 시장은 2022년부터 2029년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년부터 2029년까지의 예측 기간 동안 11.3%의 CAGR로 성장하고 있으며 2021년 2,724만 달러에서 2029년까지 6,370만 달러에 도달할 것으로 분석했습니다.
보고서 메트릭 |
세부 |
예측 기간 |
2022년부터 2029년까지 |
기준 연도 |
2021 |
역사적 연도 |
2020 (2019-2014로 사용자 정의 가능) |
양적 단위 |
수익은 백만 달러, 가격은 미화로 표시됨 |
다루는 세그먼트 |
By Source (Synthetic & Natural), Type (Empathogens, Dissociatives & Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) |
Countries Covered |
India, Australia, South Korea, Singapore, Malaysia |
Market Players Covered |
The major companies which are dealing in the market are Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.), Pfizer Inc., F. Hoffmann-La Roche Ltd, among others |
Market Definition
Psychedelic drugs involve various types of chemical substances including lysergic acid diethylamide (LSD) and chemical extracted from plants. These drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.
The psychedelic drugs can be categorized into empathogens and dissociative drugs (such as phenylcyclohexyl piperidine (PCP)) and serotonergic (classic hallucinogens) such as LSD. Both types of psychedelic drugs can cause hallucinations and feeling of sensation, moreover, dissociative drugs can make a person to fell out of control from their body or environment and makes them feel disconnected. Based on the source, psychedelic drugs have been categorized under natural and synthetic types.
These drugs have wide applications in the treatment of major depressive disorder, post-traumatic stress disorder, panic disorder, treatment-resistant depression and opiate addiction among others. Psychedelic drugs are also known by several other names such as lysergic acid derivative (LSD) which are also known as blotter, dots, sugar, acid, trips and window pane, ketamine are also known as vitamin K, bump, green, K/special K, purple and super acid, PCP are also known as angel/angel dust, boat/love boat, peace, killer weed, super grass and ozone.
Psychedelic Drugs Market Dynamics
Drivers
-
Ongoing Clinical Trials
The major depressive disorder has become a serious concern of health crisis in the modern world. The onset of clinical trials is to test the safety and efficacy of the designated drug, which is under a particular phase of a clinical trial. Depression is associated with greater deformities than most of other chronic illness and hence it poses as a risk factor for mortality. Most of the patients suffering from depression are not able to experience a complete tenacity of symptoms with antidepressant treatment. Certain clinical trials have been conducted to study the efficacy in the body. The ongoing clinical trials all over the regions would result in rapid drug approvals, enhanced drug portfolio, distribution of the psychedelics drugs in rehabilitation centres and increased awareness about the drug medication, which in turn is expected to act as driver for the growth of the market.
-
Rise In Product Approvals
The approval of psychedelic drugs depends on numerous factors, but the vital factor is the approval from the principal medical authority. The U.S. Food and Drug Administration is the leading authority for the drug approvals in the U.S. The central body decides whether the medical drugs would ultimately reach the hands of the patients. Below provided are the clinical data by established medical studies that has been reviewed by FDA in order to evaluate the feasibility of developed drug compounds or products as treatments for specific mental ailments. The rise in product approvals would result in increased distribution of the medications across national and international countries, increased safety. It would deliver a positive growth in the market.
Opportunity
-
Upcoming Rehabilitation Centers
The presence of upcoming rehabilitation centers, also termed as in patient rehabilitation hospitals would ensure the timely treatment of the patients suffering from PTSD, anxiety related disorders. These rehabilitation centers provide with the effective therapies and allow patients to achieve advanced drugs which improve the overall patient’s outcome. It would also devote to patients who would require anesthetic treatments for complicated surgeries, orthopedic, neurological, musculoskeletal, in order to stabilize the acute medical conditions.
Also, the increasing R&D activities in psychedelic drugs will provide structural integrity and future opportunities for the psychedelic drugs market in the forecast period of 2022-2029.
Restraint/Challenge
- Patent Expiry Of Psychedelic Drugs
However, the patent expiry of psychedelic drugs in some of the companies will impede the growth rate of psychedelic drugs market. Additionally, stringent rules and regulations will further challenge the market in the forecast period mentioned above.
This psychedelic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on psychedelic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Post COVID-19 Impact on Psychedelic Drugs Market
The COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world’s population. Hence, the pandemic has effected positively on this market.
Recent Developments
- In August 2020, Janssen Pharmaceuticals, Inc. received approval for its Spravato nasal spray indicated for treatment of suicidal people. As approximately 11% to 12% of Americans suffers from major depressive disorder that led them to commit suicide, this approval provided these patients with a remarkable therapy and paved the way for the company to generate more revenue.
- In January 2020, Jazz Pharmaceuticals, Inc. has received the marketing authorization of solriamfetol (Sunosi) indicated for treatment of excessive daytime sleepiness in adults with narcolepsy. This authorization allowed the company to enhance product distribution network and to generate more revenue in the market
Asia-Pacific Psychedelic Drugs Market Scope
Asia-Pacific psychedelic drugs market is segmented into source, type, drugs, application, route of administration, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Source
- Synthetic
- Natural
On the basis of source, the Asia-Pacific psychedelic drugs market is segmented into synthetic and natural.
Type
- Empathogens
- Dissociatives
- Others
On the basis of type, the Asia-Pacific psychedelic drugs market is segmented into empathogens, dissociatives, and others.
Drugs
- Gamma-Hydroxybutyric Acid
- Ketamine
- Psilocybin
- Others
On the basis of drugs, the Asia-Pacific psychedelic drugs market is segmented into gamma-hydroxybutyric acid, ketamine, psilocybin and others.
Application
- Narcolepsy,
- Treatment Resistant Depression
- Major Depressive Disorder
- Opiate Addiction
- Post-Traumatic Stress Disorder
- Others
On the basis of application, the Asia-Pacific psychedelic drugs market is segmented into narcolepsy, treatment resistant depression, major depressive disorder, opiate addiction, post-traumatic stress disorder and others.
Route of Administration
- Oral
- Inhalation
- Injectable
On the basis of route of administration, the Asia-Pacific psychedelic drugs market is segmented into oral, inhalation, injectable.
End User
- Hospital
- Specialty Clinics
- Homecare
- Others
On the basis of end user, the Asia-Pacific psychedelic drugs market is segmented into hospital, specialty clinics, homecare, and others.
Distribution Channel
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
On the basis of distribution channel, the Asia-Pacific psychedelic drugs market is segmented into hospitals pharmacy, retail pharmacy and online pharmacy.
Psychedelic Drugs Market Regional Analysis/Insights
The psychedelic drugs market is analysed and market size insights and trends are provided by country, source, type, drugs, application, route of administration, end user and distribution channel as referenced above.
The countries covered in the psychedelic drugs report are India, Australia, South Korea, Singapore and Malaysia.
India dominates the psychedelic drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to growing acceptance of psychedelic drugs for treating depression in the region and rapid research development is boosting the market.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Psychedelic Drugs Share Analysis
The psychedelic drugs market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on psychedelic drugs market.
Some of the major players operating in the psychedelic drugs market are Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.), Pfizer Inc., F. Hoffmann-La Roche Ltd, among others.
Research Methodology
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 아시아 태평양 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가 전화를 요청하십시오.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC PSYCHEDELIC DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PIPELINE ANALYSIS
4.2 PESTEL ANALYSIS
4.3 PORTER'S FIVE FORCES MODEL
5 REGULATORY FRAMEWORK: ASIA PACIFIC PSYCHEDELIC DRUGS MARKET
5.1 REGULATORY SCENARIO IN THE U.S.
5.2 REGULATORY SCENARIO IN THE U.K.
5.3 REGULATORY SCENARIO IN INDIA
5.4 REGULATORY SCENARIO IN UAE
5.5 REGULATORY SCENARIO IN AFRICA
5.6 REGULATORY SCENARIO IN BRAZIL
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS TO TREAT DEPRESSION
6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS
6.1.3 RISING AWARENESS TOWARD MENTAL HEALTH
6.1.4 ONGOING CLINICAL TRIALS
6.1.5 RISE IN PRODUCT APPROVALS
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS
6.2.2 HIGH COST OF PSYCHEDELIC DRUGS
6.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS
6.3 OPPORTUNITIES
6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS
6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY
6.3.3 UPCOMING REHABILITATION CENTERS
6.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS
6.4 CHALLENGES
6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS
6.4.2 RISE IN ILLEGAL ALTERNATIVES
6.4.3 AVAILABILITY OF OTHER TREATMENT OPTIONS
7 COVID-19 IMPACT ON THE ASIA PACIFIC PSYCHEDELIC DRUGS MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS
7.5 CONCLUSION
8 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY TYPE
8.1 OVERVIEW
8.2 EMPATHOGENS
8.3 DISSOCIATIVES
8.4 OTHERS
9 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY SOURCE
9.1 OVERVIEW
9.2 SYNTHETIC
9.3 NATURAL
10 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY DRUGS
10.1 OVERVIEW
10.2 GAMMA-HYDROXYBUTYRIC ACID
10.3 KETAMINE
10.4 PSILOCYBIN
10.5 OTHERS
11 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 NARCOLEPSY
11.3 TREATMENT RESISTANT DEPRESSION
11.4 MAJOR DEPRESSIVE DISORDER
11.5 OPIATE ADDICTION
11.6 POST-TRAUMATIC STRESS DISORDER
11.7 OTHERS
12 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.3 INHALATION
12.4 INJECTABLE
13 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 SPECIALTY CLINICS
13.4 HOMECARE
13.5 OTHERS
14 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITALS PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
15 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY REGION
15.1 ASIA-PACIFIC
15.1.1 INDIA
15.1.2 AUSTRALIA
15.1.3 SOUTH KOREA
15.1.4 SINGAPORE
15.1.5 MALAYSIA
16 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 JAZZ PHARMACEUTICALS, INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 PFIZER INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 F. HOFFMANN- LA ROCHE LTD
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 JANSSEN ASIA PACIFIC SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
18.4.1 COMPANY SNAPSHOT
18.4.2 COMPANY SHARE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENT
18.5 AVADEL
18.5.1 COMPANY SNAPSHOT
18.5.2 PRODUCT PORTFOLIO
18.5.3 RECENT DEVELOPMENT
18.6 CELON PHARMA SA
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENT
18.7 COMPASS
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENTS
18.8 CYBIN CORP.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENTS
18.9 ENTHEON BIOMEDICAL CORP
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 GH RESEARCH
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 HIKMA PHARMACEUTICALS PLC
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 NRX PHARMACEUTICALS, INC.
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 PHARMATHER HOLDINGS LTD.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 VERRIAN
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 USONAINSTITUTE.ORG
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
표 목록
TABLE 1 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, PIPELINE ANALYSIS
TABLE 2 PSYCHEDELICS RESEARCH STUDIES, IN EUROPE
TABLE 3 MENTAL ILLNESS IN THE U.S. ADULTS, IN 2020
TABLE 4 MENTAL DISORDERS, IN THE U.S. ADULTS, IN 2020
TABLE 5 DRUG DEVELOPMENT PATHWAY FOR FDA APPROVAL OF NEW MEDICATIONS
TABLE 6 THE 1971 UN CONVENTION ON PSYCHOTROPIC SUBSTANCES
TABLE 7 MAGIC MUSHROOMS PRICES FOR RESEARCHERS, IN THE U.S.
TABLE 8 COST OF PSYCHEDELIC DRUGS
TABLE 9 PSYCHEDELIC DRUGS R&D ACTIVITIES
TABLE 10 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC EMPATHOGENS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC DISSOCIATIVES IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC SYNTHETIC IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC NATURAL IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC GAMMA-HYDROXYBUTYRIC ACID IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC KETAMINE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC PSILOCYBIN IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC NARCOLEPSY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC TREATMENT RESISTANT DEPRESSION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC MAJOR DEPRESSIVE DISORDER IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC OPIATE ADDICTION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC POST-TRAUMATIC STRESS DISORDER IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC ORAL IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC INHALATION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC INJECTABLE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 ASIA PACIFIC HOSPITALS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC SPECIALTY CLINICS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC HOMECARE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 39 ASIA PACIFIC HOSPITALS PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 ASIA PACIFIC RETAIL PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 ASIA PACIFIC ONLINE PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 INDIA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 INDIA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 52 INDIA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 53 INDIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 54 INDIA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 55 INDIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 56 INDIA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 57 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 58 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 59 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 60 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 61 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 62 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 63 AUSTRALIA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 64 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 66 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 67 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 68 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 69 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 SOUTH KOREA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 73 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 74 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 75 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 76 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 77 SINGAPORE PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 78 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)
TABLE 80 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 81 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 82 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 83 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 MALAYSIA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET : DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: END USER COVERAGE GRID
FIGURE 10 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC PSYCHEDELIC DRUGS MARKET GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 RISING AWARENESS TOWARDS MERANTAL HEALTH DRIVING THE ASIA PACIFIC PSYCHEDELIC DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 EMPATHOGENS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC PSYCHEDELIC DRUGS MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC PSYCHEDELIC DRUGS MARKET
FIGURE 16 MENTAL ILLNESS AMONG THE U.S. ADULTS, IN 2020, (IN %), BY DEMOGRAPHIC GROUPS
FIGURE 17 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS, IN 2020, (IN %), BY DEMOGRAPHIC GROUPS
FIGURE 18 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS, IN 2020, (IN %), BY GENDER
FIGURE 19 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY TYPE, 2021
FIGURE 20 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 21 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 22 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2021
FIGURE 24 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2022-2029 (USD MILLION)
FIGURE 25 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY SOURCE, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2021
FIGURE 28 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2022-2029 (USD MILLION)
FIGURE 29 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DRUGS, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2021
FIGURE 32 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 33 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 36 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 37 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 38 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 39 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY END USER, 2021
FIGURE 40 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 41 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 42 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 44 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 45 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 46 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: SNAPSHOT (2021)
FIGURE 48 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021)
FIGURE 49 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 50 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 51 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: BY TYPE (2022-2029)
FIGURE 52 ASIA PACIFIC PSYCHEDELIC DRUGS MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.